This project will support a Phase 2, randomized, placebo-controlled clinical trial designed to test the effectiveness of a lung-directed immunomodulator on immune response, restoration of innate immun...
Qu Biologics Inc.
14 enregistrements totalisant 9,204,151.00 $ CAN, selon les données ouvertes officielles du gouvernement du Canada.
Intégrer ce graphique
Registre des lobbyistes — correspondance possible correspondance par nom
Une organisation portant ce nom figure dans 3 enregistrements de lobbying fédéral (0 actuellement actifs), entre 2020 et 2020.
781242-367111-2 — Summa Strategies Canada 768275-367104-1 — Summa Strategies Canada Inc. 781242-367111-1 — Summa Strategies Canada
Correspondance automatique par nom d'organisation; une autre organisation du même nom est possible. Le Registre des lobbyistes fait foi. Le lobbying est légal et encadré — ceci est du contexte, pas une allégation.
Par ministère
| Conseil national de recherches Canada | $9,204,151 | 14 enregistrements |
Enregistrements
This project will provide proof-of-concept evidence for the safety and efficacy for the prophylactic and therapeutic use of a lung-directed immunomodulator, to prevent serious COVID-19 infection.
This project aims to generate preclinical data showing that solid tumours can be better accessed and targeted by CAR T cells when the Firm's proprietary platform immunotherapy, Site-Specific Immunomod...
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
The funding provided from the IAP program is to assist innovative, early stage small-and medium-sized enterprises that are unable to access existing COVID-19 business support.
Develop processes and methods for quality control analytics and aseptic reagent and product handling, in preparation for commercial scale lot production of QBKPN, the Firm's lung-specific Site Specifi...
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
The Project will support development of intellectual property capacity within the Firm.